ArticleEuropean journal of epidemiology2026
Leukocytes and age-related macular degeneration.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Age-related macular degeneration (AMD) is a leading cause of vision loss. Leukocyte subtypes have been implicated in the pathogenesis, but causality remains uncertain. We investigated whether leukocyte counts are causally associated with clinically diagnosed AMD using observational and genetic analyses in three prospective cohorts. We included 117,714 individuals from the Copenhagen General Population Study (CGPS), 388,758 from the UK Biobank (UKB), and 285,612 from the Million Veteran Program (MVP), all of European ancestry and without clinically diagnosed AMD at baseline. In total, 27,130 incident AMD cases were identified. Baseline leukocyte counts were log2-transformed and standardized. Observational associations with incident AMD were estimated using Cox regression in CGPS and UKB, and then meta-analysed. Genetic instruments derived from genome-wide association studies were used for one-sample mendelian randomization (MR) and multivariable MR (MVMR) analyses in UKB and MVP, and estimates then meta-analysed. Observationally, a 1-standard deviation (SD) increase in leukocyte (Hazard ratio (HR) [95% confidence interval (CI)], 1.07 [1.05-1.09]), neutrophil (1.07 [1.05-1.09]), monocyte (1.05 [1.03-1.07]), basophil (1.06 [1.04-1.08]), and eosinophil (1.05 [1.03-1.06]) counts was associated with increased risk of clinically diagnosed AMD (all p < 0.0001). In the genetic analyses, a 1-SD increase in genetically determined eosinophil counts was causally associated with increased risk of clinically diagnosed AMD in the MR (OR [95% CI], 1.07 [1.00-1.15]; p = 0.038) and MVMR (OR [95% CI], 1.12 [1.03-1.21]; p = 0.006) analyses. This large-scale study provides observational and genetic evidence that elevated eosinophil counts are causally linked to risk of clinically diagnosed AMD. These findings highlight systemic eosinophil-driven immune pathways as potential contributors to AMD pathogenesis.
Indexed as
Identifiers
42902106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.